Monitor upcoming FDA feedback on trial design and the search for a new CFO, as leadership transition could impact execution despite promising clinical data.
Price Chart
Executive Summary
Fulcrum Therapeutics terminated a license agreement for its Diamond-Blackfan anemia program, reported Q1 2026 earnings with a net loss per share of $-0.25 (in line with expectations), and announced the retirement of its CFO while appointing a new board member. Despite positive clinical data for its sickle cell disease drug pociredir and a cash runway into 2029, the termination of a development program and CFO retirement create mixed sentiment.
Key Financial Metrics
Key Facts
- Terminated license agreement for Diamond-Blackfan anemia program with CAMP4 Therapeutics
- Net loss per share of $-0.25 for Q1 2026, in line with consensus estimate of $-0.30
- Cash position decreased to $333.3 million from $352.3 million in Q4 2025
- CFO Alan Musso plans to retire later this year
- Appointed Josh Lehrer, M.D., to the Board of Directors
Financial Impact
Net loss of $18.9 million for Q1 2026, cash runway into 2029
Risk Factors
- Termination of Diamond-Blackfan anemia program eliminates potential future revenue stream
- CFO retirement creates leadership uncertainty during a critical development phase
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-178806 |
| Document: fulc-20260423.htm | 0001193125-26-178806 |
| Document: 0001193125-26-178806-index-headers.html | 0001193125-26-178806 |
| Document: 0001193125-26-178806-index.html | 0001193125-26-178806 |
| Document: 0001193125-26-178806.txt | 0001193125-26-178806 |
| 8-K Data (Synthetic) | 0001193125-26-178806 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 4w ago | S-4 | $3.85 $3.70 | ▲ +3.90% | ▲ +3.57% | $3.67 (+4.68%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▲ +1.56% | ▼ −0.42% | $3.67 (+4.43%) |
Aug 17, 2026 6w ago | 425 | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | 8-K | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 17, 2026 6w ago | Press Release | $3.84 $3.78 | ▼ −1.56% | ▲ +0.42% | $3.67 (−4.43%) |
Aug 10, 2026 7w ago | 8-K | $3.75 $3.82 | ▲ +1.87% | ▲ +2.78% | $3.67 (−2.13%) |
Jul 15, 2026 11w ago | 3 | $3.50 $3.71 | ▲ +6.00% | ▲ +2.38% | $3.67 (+4.86%) |
Jun 11, 2026 16w ago | Institutional Cluster | $3.55 $3.59 | ▲ +1.13% | ▼ −0.76% | $3.67 (+3.38%) |
Apr 27, 2026 22w ago | 8-K | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
Apr 27, 2026 22w ago | Press Release | $7.72 $6.76 | ▼ −12.44% | ▼ −17.39% | $3.67 (−52.46%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access